Arecor Therapeutics plc
(“Arecor” or the “Group”)

ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR INSULIN PRODUCTS, AT278 AND AT247

Cambridge, UK, 18 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a patent (EP3618840) protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247. The European patent adds to a comprehensive global intellectual property (IP) portfolio protecting the Group’s novel insulin products and follows additional patents of similar scope recently granted in Australia, India and Mexico.

Jan Jezek, Chief Scientific Officer at Arecor, commented: “We continue to build a strong intellectual property portfolio in key markets for our ultra-fast acting insulin products, AT278 and AT247, which provide the Group significant growth potential in a multi-billion dollar market driven by the need for tighter glucose control and the rise of innovative delivery devices and digital technologies. AT278, our ‘disrupter insulin’ with its high concentration and ultra-rapid profile has the potential to be the gold standard insulin for the growing population of people with high daily insulin needs and an essential component to enable patch pump miniaturisation and extended wear-time. Further data to support its profile are expected in H1 2024 from the Group’s clinical trial in a type 2 diabetes population.”

Arecor has built a comprehensive IP portfolio protecting the Group’s Arestat™ technology platform and proprietary pipeline products. The portfolio, which comprises 36 patent families and >90 granted patents in Europe, the US and in other key territories, includes several patent families providing robust IP protection of the Group’s proprietary insulin products until at least 2037.